October 14, 2015 | Pharma giant Pfizer has invested $10 million in the Israeli bio-medical company Protalix Biotherapeutics in exchange for a six percent share in the Karmiel-based company.
Protalix has also given Pfizer full commercial rights to the Gaucher disease treatment Elelyso in all countries except Brazil in exchange for $36 million cash. Since the companies’ first strategic agreement six years ago, Protalix has replaced its management and changed its business strategy, now lead by new CEO Moshe Manor. The company was founded in 1993 by biochemist Yoseph Shaaltiel, who developed the principle plant-based enzyme used in Elelyso.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments